Teva/Ivax closing date extended
Executive Summary
The closing date for Teva's acquisition of Ivax has been extended, Teva announces Jan. 10; the consent order for the acquisition is still under review by the Federal Trade Commission, company reports. The two generics firms "have no reason to believe that the acceptance will not be forthcoming shortly, and expect to close the merger later this month." Teva announced the $7.4 bil. acquisition in July 2005 (1"The Pink Sheet" Aug. 1, 2005, p. 19)...